Stryker Corp
- NYSE
- SYK
- CIK
- 310764
- Based in
- Portage, Michigan
- Incorporated in
- Michigan
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Employer ID (EIN)
- 38-1239739
About
AI summary. This paragraph was summarized by AI from the company’s annual report. It may contain mistakes: check it against the source. How it was written
Stryker Corporation is a medical technology company incorporated in Michigan in 1946 as the successor to a business founded in 1941 by orthopaedic surgeon Dr. Homer H. Stryker. It operates in two reportable segments. MedSurg and Neurotechnology includes Instruments (surgical equipment and navigation systems), Endoscopy (endoscopic and communications systems), Medical (patient handling, emergency medical equipment, intensive care disposables and clinical communication platforms), Vascular (minimally invasive stroke and venous thromboembolism products) and Neuro Cranial. Orthopaedics provides implants for hip, knee, shoulder, ankle, and trauma and extremities surgeries, along with Mako robotic-arm assisted technology. Most products are marketed directly to doctors, hospitals and other healthcare facilities. They are sold in approximately 61 countries through company-owned subsidiaries and branches and through third-party dealers and distributors.
Source: the Business section of the company’s 10-K filed Feb 11, 2026.
Key figures
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | $25.1B | $22.6B | $20.5B | $18.4B | $17.1B |
| Operating income | $4.89B | $3.69B | $3.89B | $2.84B | $2.58B |
| Net income | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B |
| Diluted EPS | $8.40 | $7.76 | $8.25 | $6.17 | $5.21 |
| Cash from operations | $5.04B | $4.24B | $3.71B | $2.62B | $3.26B |
| Total assets | $47.8B | $43.0B | $39.9B | $36.9B | $34.6B |
| Shareholders’ equity | $22.4B | $20.6B | $18.6B | $16.6B | $14.9B |
From the company’s annual reports to the SEC. Each year links to its report.
Financials 137
- 10-Q Quarterly Report for period ending Sep 30, 2026
- 10-Q Quarterly Report for period ending Jun 30, 2026
- 10-Q Quarterly Report for period ending Mar 31, 2026
- 10-K Annual Report for period ending Dec 31, 2025
- 10-Q Quarterly Report for period ending Sep 30, 2025
- 10-Q Quarterly Report for period ending Jun 30, 2025
- 10-Q Quarterly Report for period ending Mar 31, 2025
- 10-K Annual Report for period ending Dec 31, 2024
- 10-Q Quarterly Report for period ending Sep 30, 2024
- 10-Q Quarterly Report for period ending Jun 30, 2024
News 268
- 8-K Director or officer change; Regulation FD disclosure
- 8-K Financial results
- 8-K Director or officer change; Regulation FD disclosure
- 8-K Financial results
- 8-K Other events
- 8-K Director or officer change
- 8-K Shareholder vote results
- 8-K Financial results
- 8-K/A Cybersecurity incident; Regulation FD disclosure
- 8-K Regulation FD disclosure
Ownership 2,210
- 4 Stryker Ronda E (Director): acquired 3,605 shares from options or stock units
- 4 Stryker Ronda E (Director): sold 550,000 shares at an average of $325.32 ($178.9M)
- 144 Stryker Ronda E (Director): plans to sell 550,000 shares ($186.8M)
- 4 Change in insider ownership
- 4 Change in insider ownership
- 3 Initial statement of insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
- 4 Change in insider ownership
Prospectus 117
- S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
- S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
- SC TO-T/A Inari Medical, Inc.: Third party tender offer statement
- SC TO-T/A Third party tender offer statement
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
- 424B5 Prospectus filed pursuant to Rule 424(b)(5)
- SC TO-T Third party tender offer statement
- SC TO-C Written communication relating to an issuer or third party tender offer
- SC TO-C Written communication relating to an issuer or third party tender offer
Proxies 56
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
- DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
- DEF 14A Definitive proxy statements
Other 95
- IRANNOTICE Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
- SD Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
- SD Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
- IRANNOTICE Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
- 25-NSE Removal from exchange listing
- CERT Certification by an exchange approving securities for listing
- 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
- SD Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
- CERT Certification by an exchange approving securities for listing
- 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)